Benzodiazepine receptor agonists and insomnia: Is subtype selectivity lost in translation?

Drug Discovery Today: Therapeutic Strategies

Volumn 3, Issue 4, 2006, Pages 547-554

  Ebert, Bjarke ^a   Wafford, Keith A ^b  

^a H LUNDBECK A S   (Denmark)

^b MSDRL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; BENZODIAZEPINE; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; DIAZEPAM; ESZOPICLONE; FLURAZEPAM; GABOXADOL; INDIPLON; ION CHANNEL; MELATONIN; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; TEMAZEPAM; TRIAZOLAM; ZALEPLON; ZOLPIDEM TARTRATE; ZOPICLONE;

4 AMINOBUTYRIC ACID UPTAKE; BINDING SITE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDICATION; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SELECTIVITY; DRUG TARGETING; GENE TARGETING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INSOMNIA; NONHUMAN; PROTEIN LOCALIZATION; REVIEW; TISSUE DISTRIBUTION;

EID: 33846180018     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2006.11.008     Document Type: Review

References (44)

1. Book Review. The elusive magic bullet: the search for the perfect drug. N. Engl. J. Med. 341 (1999) 1320-1321
2. Mah F.S. New antibiotics for bacterial infections. Ophthalmol. Clin. North. Am. 16 (2003) 11-27
3. Murphy D.L., et al. Brain serotonin neurotransmission: an overview and update with an emphasis on serotonin subsystem heterogeneity, multiple receptors, interactions with other neurotransmitter systems, and consequent implications for understanding the actions of serotonergic drugs. J. Clin. Psychiatry 59 Suppl. 15 (1998) 4-12
4. Holtzheimer III P.E., and Nemeroff C.B. Advances in the treatment of depression. NeuroRx 3 (2006) 42-56
5. A receptors. Neurochem. Int. 34 (1999) 379-385
6. A receptor gene family. Ann. N. Y. Acad. Sci. 868 (1999) 645-653
7. A receptor subtypes. Curr. Top. Med. Chem. 2 (2002) 795-816
8. A receptors: immunocytochemical distribution of 13 subunits in the adult rat brain. Neuroscience 101 (2000) 815-850
9. A receptors. Trends Neurosci. 27 (2004) 569-575
10. A receptors to synaptic and extrasynaptic membranes of cerebellar granule cells. J. Neurosci. 18 (1998) 1693-1703
11. A receptors. Br. J. Pharmacol. 136 (2002) 965-974
12. A receptor subunits: role of the delta subunit. J. Neurosci. 14 (1994) 7077-7086
13. A-receptor subtypes really occur in the brain?. Trends Neurosci. 19 (1996) 139-143
14. Mohler H., et al. A new benzodiazepine pharmacology. J. Pharmacol. Exp. Ther. 300 (2002) 2-8
15. A receptor alpha1 subtype. Nat. Neurosci. 3 (2000) 587-592
16. A receptors in mediating the anxiolytic effects of benzodiazepines. J. Neurosci. 25 (2006) 10682-10688
17. A receptor: an old target with new potential?. Sleep Med. 5 Suppl. 1 (2004) S9-S15
18. Sigel E. Mapping of the benzodiazepine recognition site on GABA(A) receptors. Curr. Top. Med. Chem. 2 (2002) 833-839
19. A receptors. Neuropsychopharmacology 20 (1999) 255-262
20. A receptor subtypes. Eur. J. Pharmacol. 451 (2002) 103-110
21. A receptors. J. Pharmacol. Exp. Ther. 317 (2006) 369-377
22. Saper C.B., et al. Hypothalamic regulation of sleep and circadian rhythms. Nature 437 (2005) 1257-1263
23. National Institute for Clinical Excellence. (2004) Technology Appraisal Guidance 77. Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia. National Institute for Clinical Excellence (Available at: http://www.nice.org.uk/TA077guidance/)
24. Foster A.C., et al. In vivo pharmacological characterization of indiplon, a novel pyrazolopyrimidine sedative-hypnotic. J. Pharmacol. Exp. Ther. 311 (2004) 547-559
25. Wala E.P., et al. Brain-plasma distribution of free and total benzodiazepines in dogs physically dependent on different doses of diazepam. Pharmacol. Biochem. Behav. 52 (1995) 707-713
26. A receptors for the development of tolerance to the sedative action of diazepam in mice. J. Neurosci. 24 (2004) 6785-6790
27. A receptor subtypes mediate the anxiolytic, abuse-related, and motor effects of benzodiazepine-like drugs in primates. Proc. Natl. Acad. Sci. U S A 102 (2005) 915-920
28. A receptors. J. Neurosci. 23 (2003) 11158-11166
29. Wafford K.A., and Ebert B. Gaboxadol - a new awakening in sleep. Curr. Opin. Pharmacol. 6 (2006) 30-36
30. A receptors of thalamocortical neurons: a molecular target for hypnotics. J. Neurosci. 25 (2005) 11513-11520
31. A receptor mediates tonic inhibition in thalamic VB neurons. J. Neurophysiol. 94 (2005) 4491-4501
32. A receptor-mediated conductance in mouse neocortex. Cereb. Cortex (2005) [EPub ahead of print]
33. A receptor agonists in rhesus monkeys. Psychopharmacology (Berl) 178 (2005) 400-409
34. A receptor agonist gaboxadol: lack of ethanol potentiation and benzodiazepine cross-tolerance. Eur. J. Pharmacol. 482 (2003) 215-222
35. Storustovu S., and Ebert B. Gaboxadol: in vitro interaction studies with benzodiazepines and ethanol suggest functional selectivity. Eur. J. Pharmacol. 467 (2003) 49-56
36. Mathias S., et al. Effect of repeated gaboxadol administration on night sleep and next-day performance in healthy elderly subjects. Neuropsychopharmacology 30 (2005) 833-841
37. A agonist gaboxadol on nocturnal sleep and hormone secretion in healthy elderly subjects. Am. J. Physiol. Endocrinol. Metab. 281 (2001) E130-E137
38. Lancel M. The GABA(A) agonist THIP increases non-REM sleep and enhances non-REM sleep-specific delta activity in the rat during the dark period. Sleep 20 (1997) 1099-1104
39. Lundahl J., et al. Gaboxadol improves sleep maintenance and, in contrast to zolpidem, enhances slow wave sleep in adult patients with primary insomnia. 159th Annual Meeting of the American Psychiatric Association, 20-25 May 2006. Toronto, Canada (2006) (Abstract NR 823)
40. Echizenya M., et al. Heat loss, sleepiness, and impaired performance after diazepam administration in humans. Neuropsychopharmacology 28 (2003) 1198-1206
41. Villikka K., et al. The effect of dexamethasone on the pharmacokinetics of triazolam. Pharmacol. Toxicol. 83 (1998) 135-138
42. Greenblatt D.J., et al. Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo. Clin. Pharmacol. Ther. 64 (1998) 553-561
43. Villikka K., et al. Concentrations and effects of zopiclone are greatly reduced by rifampicin. Br. J. Clin. Pharmacol. 43 (1997) 471-474
44. Ebert B., et al. Treating insomnia: current and investigational pharmacological approaches. Pharmacol. Ther. 112 (2006) 612-629